LEADER 04241nam  2200661Ia 450 
001 9910967295803321
005 20251117072648.0
010   $a9786612412547
010   $a9781282412545
010   $a128241254X
010   $a9780309138376
010   $a030913837X
035   $a(CKB)2420000000001444
035   $a(EBL)3378540
035   $a(SSID)ssj0000438155
035   $a(PQKBManifestationID)12160749
035   $a(PQKBTitleCode)TC0000438155
035   $a(PQKBWorkID)10452362
035   $a(PQKB)11642112
035   $a(MiAaPQ)EBC3378540
035   $a(Au-PeEL)EBL3378540
035   $a(CaPaEBR)ebr10347043
035   $a(CaONFJC)MIL241254
035   $a(OCoLC)923280906
035   $a(Perlego)4734414
035   $a(BIP)27376649
035   $a(EXLCZ)992420000000001444
100   $a20090921d2009      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aInitial national priorities for comparative effectiveness research /$fCommittee on Comparative Effectiveness Research Prioritization, Board on Health Care Services, Institute of Medicine of the National Academies
205   $a1st ed.
210   $aWashington, D.C. $cNational Academies Press$dc2009
215   $a1 online resource (252 p.)
300   $aDescription based upon print version of record.
311 08$a9780309138369 
311 08$a0309138361 
320   $aIncludes bibliographical references.
327   $a""Reviewers""; ""Foreword""; ""Preface""; ""Acknowledgments""; ""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 What Is Comparative Effectiveness Research?""; ""3 Obtaining Input to Identify National Priorities for Comparative Effectiveness Research""; ""4 The Criteria and Process for Setting Priorities""; ""5 Priorities for Study""; ""6 Essential Priorities for a Robust CER Enterprise""; ""Appendix A: Public Meeting Agendaa???March 20, 2009""; ""Appendix B: Stakeholder Questionnaire""; ""Appendix C: Data Tables: Burden of Disease and Variation of Care""
327   $a""Appendix D: Cardiovascular and Peripheral Vascular Cover Sheet""""Appendix E: Definitions of Medical Terminology in CER Priority List""; ""Appendix F: Committee Biographies""
330   $aClinical research presents health care providers with information on the natural history and clinical presentations of disease as well as diagnostic and treatment options. In today's healthcare system, patients, physicians, clinicians and family caregivers often lack the sufficient scientific data and evidence they need to determine the best course of treatment for the patients' medical conditions. Initial National Priorities for Comparative Effectiveness Research (CER) is designed to fill this knowledge gap by assisting patients and healthcare providers across diverse settings in making more informed decisions. In this 2009 report, the Institute of Medicine's Committee on Comparative Effectiveness Research Prioritization establishes a working definition of CER, develops a priority list of research topics, and identifies the necessary requirements to support a robust and sustainable CER enterprise.   As part of the 2009 American Recovery and Reinvestment Act, Congress appropriated $1.1 billion in federal support of CER, reflecting legislators' belief that better decisions about the use of health care could improve the public's health and reduce the cost of care. The Committee on Comparative Effectiveness Research Prioritization was successful in preparing a list 100 top priority CER topics and 10 recommendations for best practices in the field.
517 3 $aComparative effectiveness research
606   $aMedicine$xResearch$zUnited States
606   $aMedical policy$zUnited States
615  0$aMedicine$xResearch
615  0$aMedical policy
676   $a610.72073
712 02$aInstitute of Medicine (U.S.).$bCommittee on Comparative Effectiveness Research Prioritization.
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910967295803321
996   $aInitial national priorities for comparative effectiveness research$94362524
997   $aUNINA